Senior Scientific Staff
Andrew Cherniack, PhD
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Group Leader, Computational Biology
2010-
PhD, The Ohio State University
Phone|Email
My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.
Heidi Greulich, PhD
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Senior Group Leader/Director, Cancer Therapeutic Projects
2004-
PhD, The Rockefeller University
Phone|Email|LinkedIn
My group studies therapeutic targets identified from cancer genomic data with the goal of developing new cancer treatments. Target classes include mutated receptor tyrosine kinases, epigenetic targets, and small molecules that cause complex formation between PDE3A and SLFN12, inducing death of cancer cells expressing elevated levels of these two proteins.
Jodi Hirschman, PhD
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Research Program Manager
2019-
PhD, University of California, Davis
Email|LinkedIn
I am the Research Program Manager both for the Meyerson laboratory and for Grand Challenge OPTIMISTICC project. For the former, I help with the writing and submission of research proposals and other communications; for the OPTIMISTICC project, I coordinate communications and events for the 13-lab consortium, and assist with scientific strategy.
Kristyna Kotynkova, PhD
Research Scientist I
2022-
PhD, University College London (Francis Crick Institute)
I am studying the mechanism of novel cancer therapeutics that target tumor cells expressing high levels of PDE3A and SLFN12. Outside the lab, I enjoy hiking, birding and rock climbing.
Research Scientist I
2022-
PhD, University College London (Francis Crick Institute)
I am studying the mechanism of novel cancer therapeutics that target tumor cells expressing high levels of PDE3A and SLFN12. Outside the lab, I enjoy hiking, birding and rock climbing.
Yvonne Li, PhD, FACMG
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
PhD, University of British Columbia, Canada
I collaborate with DFCI oncologists to leverage Profile OncoPanel targeted panel sequencing data for genomic analysis and clinical correlation.
Gizem Karsli Uzunbas, PhD
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Research Scientists II
2019-
PhD, Rutgers University
Email|LinkedIn
My research goal is to develop new therapeutic approaches to treat lung cancers with mutations identified by tumor sequencing.
Junior Scientific Staff
Sawyer Andersen, B.S.
Research Associate
2022-
B.S., University of Massachusetts Amherst
I am working to understand the mechanisms of novel cancer therapeutics that target tumor cells expressing high levels of SLFN12.
Vincent Bozinov, B.S.
Research Associate
2022-
B.S., Neuroscience, Baylor University
The research I am involved in focuses on telomerase and ALT and using them as a possible target against cancer cell immortality in glioblastomas.
Diego Capcha, B.S.
Associate Computational Biologist
2023-
B.S., Haverford College
I am researching how to leverage the innate immune system to induce cell lethality in lung cancer cell lines.
Associate Computational Biologist
2023-
B.S., Haverford College
I am researching how to leverage the innate immune system to induce cell lethality in lung cancer cell lines.
Katherine Cho, B.S.
Research Associate
2022-
B.S., Johns Hopkins University
I am interested in examining why U2AF1 S34F mutations are selected for in lung adenocarcinomas.
Research Associate
2022-
B.S., Johns Hopkins University
I am interested in examining why U2AF1 S34F mutations are selected for in lung adenocarcinomas.
Allison Chou, B.A.
Research Associate
2023-
B.A., Princeton University
I work on developing novel cancer treatments for lung cancers with receptor tyrosine kinase mutations.
Research Associate
2023-
B.A., Princeton University
I work on developing novel cancer treatments for lung cancers with receptor tyrosine kinase mutations.
Akansha Gupta, B.S.
Associate Computational Biologist
2022-
B.S., University of Wisconsin-Madison
My work focuses on performing genomic analyses to identify new targets for cancer therapeutics. Additionally, I analyze copy number alterations and rearrangements for projects with the National Cancer Institute's Genomic Data Analysis Network (GDAN).
Associate Computational Biologist
2022-
B.S., University of Wisconsin-Madison
My work focuses on performing genomic analyses to identify new targets for cancer therapeutics. Additionally, I analyze copy number alterations and rearrangements for projects with the National Cancer Institute's Genomic Data Analysis Network (GDAN).
Kevin Jiang, B.S.
Research Associate
2022-
B.S., University of California, Los Angeles
I am working on researching the influence of Fusobacterium on colorectal cancer and the tumor microenvironment.
Research Associate
2022-
B.S., University of California, Los Angeles
I am working on researching the influence of Fusobacterium on colorectal cancer and the tumor microenvironment.
Ananya Kodali, B.S.
Bioinformatics Analyst
2023-
B.S., University of Texas at Austin
I conduct genomic analyses of targeted sequencing data from oncology patients.
Bioinformatics Analyst
2023-
B.S., University of Texas at Austin
I conduct genomic analyses of targeted sequencing data from oncology patients.
Iris Lee, B.S.
Associate Computational Biologist
2023-
B.S., California Institute of Technology
I am working on identifying microbes active in Age-Related Macular Degeneration (AMD) and colorectal cancer.
Associate Computational Biologist
2023-
B.S., California Institute of Technology
I am working on identifying microbes active in Age-Related Macular Degeneration (AMD) and colorectal cancer.
Ethan Shurberg, B.S.
Associate Computational Biologist
2023-
B.S., Brandeis University
I'm researching the associations between population ancestry and EGFR-mutant lung adenocarcinoma.
Associate Computational Biologist
2023-
B.S., Brandeis University
I'm researching the associations between population ancestry and EGFR-mutant lung adenocarcinoma.